* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Admissions:
None
Delistings:
None
What’s baking in the oven?
It's a little empty
Banquet Buffet****
London Stock Exchange: Main Market and AIM
Audioboom Group 497.5p £90.59m (BOOM.L)
The global Company announced its unaudited half-year results for the six months ended 30 June 2026. The H1 adjusted EBITDA profit was US$3.2m, up 80% on H1 2025 US$1.8m, highlighting the continued strong performance of the business, with adjusted EBITDA profit expected to continue to be a proxy for cash generation going forward. H1 gross profit was US$9.9m, up 33% on H1 2025 US$7.4m, representing a gross margin of 22% (H1 2025: 21%). The Group cash as at 30 June 2026 was US$5.4m, with a further US$3.3m available via an overdraft facility, and the Company has reached agreement in principle with HSBC on a new revolving credit facility of up to US$10m to support the Group's growth strategy, with the facility expected to complete in the coming weeks. The Company has booked more than US$81m in revenue for 2026 as of 14 July 2026 - ahead of total 2025 revenue of US$80.4m, with the seasonally highest-demand period still ahead.
Beeks Financial Cloud Group 202.50p £146.92m (BKS.L)
The cloud computing and connectivity provider for financial markets provided an update for the financial year ended 30 June 2026. FY26 demonstrates another year of strong financial performance, in line with the Board's expectations, reflecting a record H2 and continued commercial momentum across the Group. FY26 Revenue is expected to increase by 11% to approximately £40.0m (FY25: £35.9m), with underlying EBITDA growth of 18% to approximately £16.0m (FY25: £13.6m) and underlying profit before tax growth of 13% to approximately £6.2m (FY25: £5.5m). On a constant currency basis, Beeks has achieved revenue growth of 12% at £40.7m and underlying profit before tax growth of 18% to £6.5m. Beeks demonstrated Private Cloud growth and the benefits of Exchange Cloud revenue share contracts, providing a strong underpin to FY27 performance.
Eco Animal Health Group 89.0p £58.27m (EAH.L)
The global animal health Company developing and marketing branded veterinary products to improve livestock productivity and welfare announces its audited results for the year ended 31 March 2026. Revenue was ahead and adjusted EBITDA 4% ahead of upgraded market expectations following strong second half to the year. Group sales were £87.5m, up from £79.6m in 2025, an increase of 10%. North America revenue grew 22% (28% constant currency), contributing a growing share of Group revenues, while Latin America revenue grew 15% (21% constant currency), driven by Brazil. The adjusted EBITDA was £8.5m, an increase of 16% and 5% ahead of consensus. The Aivlosin demand continues to be robust in key markets, with particular growth in North America, Latin America and South East Asia.
EDX Medical Group 10.75p £43.26m (EDX.L)
The Company which develops innovative digital diagnostic products and services supporting personalised treatments for major diseases is launching a new health and wellbeing screening service in the UK which features comprehensive tests for employees. The service will involve general health checks and will also include biomarker testing panels that determine risk of cancer, cardiovascular disease and metabolic disorders. The health screening service will comprise a series of comprehensive panels of 40 to 80 biomarkers covering more than 100 disease conditions. An agreement has been reached in principle with three significant UK employers, a total of 14,000 employees, to undertake health screening, subject to final documentation. The Company estimates that, on the basis of the current agreements in principle, fulfilment of these agreements could generate revenue in excess of £2m this financial year, with repeat testing to be carried out in future years.
GETECH Group 2.15p £3.28m (GTC.L)
The locator of subsurface resources announced that it has signed a multi-year agreement with a European headquartered oil and gas super major for access to its industry leading Globe platform. The new contract has a total value of $660k to be recognised over three years as annual recurring revenue. This new contract means that five of the world's six recognised oil and gas super majors now rely on Globe for subsurface intelligence alongside numerous other international operators and national oil companies. Globe is a unique exploration resource that provides comprehensive subsurface insights derived from the analysis of 400 million years of geological history, including earth structure, tectonic evolution and climate development. Energy explorers use Globe alongside proprietary data to identify new exploration concepts, evaluate potential assets and enhance decision-making.
Iofina 57.50p £106.48m (IOF.L)
The specialists in the exploration and production of iodine and manufacturers of specialty chemical products updated on its activities during H1 2026. During the Period, Iofina Resources produced a record 393.3 metric tonnes of crystalline iodine from its eight IOsorb plants in Oklahoma, up 29% on H1 2025 (305.5 metric tonnes). The production also exceeded the Company's previously upgraded guidance of 385 metric tonnes. The record performance reflects strong operational execution across all production sites, with better-than-expected brine volumes at the Company's central Oklahoma plants. Construction of the Company's largest IOsorb plant, IO#12, in the Permian Basin, in partnership with Western Midstream Partners, is progressing well and on track. The Company anticipates commissioning the new facility during Q3 2026, with production expected to commence towards the end of September. Once operational, IO#12 is expected to contribute 170-220 metric tonnes of crystalline iodine annually. Demand for crystalline iodine remains robust, with pricing during H1 2026 remaining consistent with 2025 levels. Spot iodine prices continue to trade in the mid-US$70/kg range and the Company expects market conditions to remain favourable through the second half of the year.
Lendinvest 27.00p £35.98m (LINV.L)
The platform Company for property finance today released its FY26 Financial Results. Net operating income increased 12% to £43.2m (FY25: £38.6m), of which £19.7m came from net interest income from principal investments, £23.7m came from net fee income from third party assets, and net gains on sale of loans to third parties was £1.4m. Administrative expenses decreased 1% to £36m with underlying administrative expenses decreasing 5% to £33.3m, despite materially higher Assets under Management (AUM) and lending volumes. The underlying PBT was £4.0m, while adjusted EBITDA increased 200% to £8.7m. AUM increased 18% to £3.82bn, of which 75% was third party AUM. The Company entered FY27 with it largest lending pipeline to date.
Savannah Resources 6.45p £160.97m (SAV.L)
The developer of the Barroso Lithium Project in Portugal, a 'Strategic Project' under the European Critical Raw Materials Act and Europe's largest spodumene lithium deposit, announced the Project's first Ore Reserve Estimate. The 20m tonnes Reserve at 0.99% Li2O has been estimated by Snowden Optiro from the c.27m tonnes of combined Measured and Indicated Resources, which form part of the Project's overall current 39m tonnes JORC Compliant Resource, recently updated by Ashmore Advisory. The Reserve is based on a conservative concentrate price of US$1,200/t 6% Li2O vs. current spot prices of c.US$2,250/t.
Zenith Energy 4.85p £33.59m (ZEN.L)
The energy Company has signed a Memorandum of Understanding (MoU) with a renewable energy operator for the sale of a portfolio of solar development projects located in the Piedmont region of Italy, with an aggregate expected installed capacity of approximately 50 MWp, for a total consideration of EUR 12m. The aggregate acquisition and development cost of the Piedmont Portfolio is expected to be approximately EUR 5m upon completion, implying a gross profit of approximately EUR 7m on the Proposed Transaction. The MoU follows the Company's announcement on July 13 that it was in advanced discussions regarding the disposal of a solar development project and, if completed, would represent the first monetisation of Zenith's Italian solar portfolio.
AQSE Market
Hydro Hotel Eastbourne 700.0p £4.2m (AQSE:HYDP)
The hotel operator reported interim results for the half year ended 30 April 2026. The total turnover for the six month period to 30 April 2026 was over £2.18m, an increase of 2% from the same period in the previous year. The gross profit for the period was 3% higher than in the six months to 30 April 2025. Staff costs increased by 8% compared to the figure for the period to 30 April 2025 (10% increase in staff costs in the half year to 30 April 2025). Overheads increased by 12% (8% increase in the half year ended 30 April 2025). There was an increase in repair, refurbishment and replacement costs too and this, together with the increases in business rates and utilities, contributed to the increase in overhead expenses during the period. There is an increase in the loss for the half year to 30 April 2026 to £212,442, compared to a loss of £97,225 for the half year to 30 April 2025. The Board and the management of the Company continue to monitor cash resources and have paid a dividend of £90,000 declared on 25 February.
What’s baking in the oven?
Potential IPOs:***
Dual List:***
Bravura Solutions (ASX: BVS) the global provider of enterprise software for the wealth management and funds administration industries has announced its intention to dual list on AIM. Bravura is currently listed on the Australian Securities Exchange (ASX) and Admission to AIM is being sought via the AIM Designated Market Route. No capital to be raised on Admission with a market cap on Admission of circa £500m. Expected Admission date is 28 July.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
